LLY vs. JNJ, MRK, PFE, BMY, NVO, AZN, NVS, ABT, SNY, and UNH
Should you be buying Eli Lilly and stock or one of its competitors? The main competitors of Eli Lilly and include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Novartis (NVS), Abbott Laboratories (ABT), Sanofi (SNY), and UnitedHealth Group (UNH). These companies are all part of the "medical" sector.
Eli Lilly and vs.
Eli Lilly and (NYSE:LLY) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, community ranking, valuation and earnings.
Eli Lilly and pays an annual dividend of $4.52 per share and has a dividend yield of 1.0%. Johnson & Johnson pays an annual dividend of $4.76 per share and has a dividend yield of 3.0%. Eli Lilly and pays out 71.9% of its earnings in the form of a dividend. Johnson & Johnson pays out 99.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
In the previous week, Johnson & Johnson had 7 more articles in the media than Eli Lilly and. MarketBeat recorded 23 mentions for Johnson & Johnson and 16 mentions for Eli Lilly and. Eli Lilly and's average media sentiment score of 0.31 beat Johnson & Johnson's score of 0.11 indicating that Eli Lilly and is being referred to more favorably in the media.
Eli Lilly and has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.
Johnson & Johnson has higher revenue and earnings than Eli Lilly and. Johnson & Johnson is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.
82.1% of Eli Lilly and shares are held by institutional investors. Comparatively, 67.9% of Johnson & Johnson shares are held by institutional investors. 0.1% of Eli Lilly and shares are held by insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Eli Lilly and has a net margin of 20.54% compared to Johnson & Johnson's net margin of 13.22%. Eli Lilly and's return on equity of 61.42% beat Johnson & Johnson's return on equity.
Eli Lilly and currently has a consensus target price of $425.05, suggesting a potential downside of 4.22%. Johnson & Johnson has a consensus target price of $171.57, suggesting a potential upside of 8.08%. Given Johnson & Johnson's higher possible upside, analysts clearly believe Johnson & Johnson is more favorable than Eli Lilly and.
Eli Lilly and received 79 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 70.51% of users gave Eli Lilly and an outperform vote while only 64.87% of users gave Johnson & Johnson an outperform vote.
Summary
Eli Lilly and beats Johnson & Johnson on 12 of the 20 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LLY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eli Lilly and Competitors List
Related Companies and Tools
